Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

RNA cytosine modifications regulates musculoskeletal disorders.

Created on 28 Jul 2026

Authors

Haitao Wang, Peirui Ke, Xing Zhao, Shuying Shen

Published in

Molecular biology reports. Volume 53. Issue 1. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

The RNA cytosine modification (RCM), particularly 5-methylcytosine (m5C) and N4-acetylcytidine (ac4C) modification, represents a rapidly advancing frontier in recent epitranscriptomic research. These reversible modifications intervene in the process of RNA generation, thus playing a critical role in the post-transcriptional regulation of RNA, including nuclear export, ribosome assembly, translation, and stability, thereby modulating various fundamental biological processes, such as cellular proliferation, differentiation, and cell death. Musculoskeletal disorders (MSDs), including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), osteosarcoma (OS), and intervertebral disc degeneration (IVDD), are a major class of debilitating conditions that affect the locomotor system. Emerging evidence has demonstrated that dysregulation of m5C or ac4C modification contributes significantly to MSD pathogenesis through multiple mechanisms, including chondrocyte pyroptosis, lipid droplet dynamics, macrophage polarization, osteogenic and osteoclastic differentiation, synovial hyperplasia and invasion, and tumor-associated metabolic reprogramming. Moreover, these modifications are mechanistically linked to key pathological hallmarks, such as immune cell infiltration, ferroptosis, autophagy, and aberrant mechanical compression transduction. Pharmacological targeting of m⁵C- and ac⁴C-regulatory enzymes has been indicated to have therapeutic potential in animal models of MSDs. Herein, we present this review that systematically addresses the molecular basis and current knowledge on the mechanisms underlying RCMs in a variety of MSDs, along with translational strategies targeting these epitranscriptomic pathways. Finally, we present our thoughts and comments on this topic.

PMID:
42517944
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement